看多
Inovio Pharmaceuticals Provides another great entry opportunity
Inovio announced (July 23 / 2014) HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial. The price per share closed today @ $12.63, that's 11% lower than the post-announcement high of $14.20 and 20% lower than the 52 week high of $15.80.
As the market digests this HUGE news and we await "detailed study findings will be submitted for publication in a peer-reviewed scientific journal", I would expect to see some extreme volatility to continue.
I have a long position ACB $8.20 and I actively swing-trade as opportunities arise. Pull-back(s) such as where we are now are the opportunities I seek.
I expect to see many upgrades in the near future and the possibility(s) of partnerships could be announced anytime. As with any small-cap bio stock, dilution is a possibility in order to fund ongoing phase 1 & 2 clinical trials or future phase 3 trials.
**Note** I am particularly interested in the possibility of a gap (getting filled) that formed on the daily chart on July 23rd (phase 2 data released) @ $11.60 - $12.00.
Hope you enjoy the chart and have great trades in the future.
As the market digests this HUGE news and we await "detailed study findings will be submitted for publication in a peer-reviewed scientific journal", I would expect to see some extreme volatility to continue.
I have a long position ACB $8.20 and I actively swing-trade as opportunities arise. Pull-back(s) such as where we are now are the opportunities I seek.
I expect to see many upgrades in the near future and the possibility(s) of partnerships could be announced anytime. As with any small-cap bio stock, dilution is a possibility in order to fund ongoing phase 1 & 2 clinical trials or future phase 3 trials.
**Note** I am particularly interested in the possibility of a gap (getting filled) that formed on the daily chart on July 23rd (phase 2 data released) @ $11.60 - $12.00.
Hope you enjoy the chart and have great trades in the future.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。